Blueprint Medicines Corp (NAS:BPMC)
$ 104.45 -0.51 (-0.49%) Market Cap: 6.54 Bil Enterprise Value: 6.26 Bil PE Ratio: 0 PB Ratio: 21.06 GF Score: 72/100

Blueprint Medicines Corp at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 02:10PM GMT
Release Date Price: $96.02 (-1.12%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everybody. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech equity analysts at Barclays. And I just want to thank everyone for taking time out of their day. And if you have questions, institutional investors can e-mail me at [email protected] or find me on Bloomberg.

And it gives me great pleasure to introduce the management team from Blueprint. And I have with me Christina Rossi, Chief Commercial Operator; and Becker Hewes, the Chief Medical Officer at Blueprint.

Questions & Answers

Peter Richard Lawson;Christina Rossi
Barclays Bank PLC, Research Division - Research Analyst;Blueprint

And I guess with that, just as an initial question, just -- and I've been asking my question -- my companies this over the last couple of days. What's the core competency do you think of Blueprint? And yes, just start there, and we dive into questions around GIST, et cetera.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot